HIV clinical outcomes among people with HIV and diabetes mellitus in Kampala, Uganda; A matched retrospective cohort study.

Suppressive antiretroviral treatment (ART) has resulted into prolonged survival of people with HIV (PWH) in Sub-Saharan Africa (SSA) with resultant increase in the incidence of non-communicable diseases (NCD), such as diabetes mellitus (DM). However, there is a lack of data on the effect of DM on HIV-related outcomes among PWH in this setting. The study aimed to compare HIV clinical outcomes (viral load suppression, retention in care, hospitalization, tuberculosis, and mortality) between PWH with DM and those without at two large HIV clinics in Kampala, Uganda.

Determinants of continuation on HIV pre-exposure propylaxis among female sex workers at a referral hospital in Uganda: a mixed methods study using COM-B model.

Background: Female sex workers (FSWs) have the highest HIV prevalence in Uganda. Pre-exposure prophylaxis (PrEP) has been recommended as a key component of the HIV combination prevention strategy. Although patient initiation of PrEP has improved, continuation rates remain low.

Provider assisted partner notification utilization and associated factors among adolescents living with HIV in Uganda, a cross-sectional study.

Background: Assisted Partner Notification (APN) is a high yield HIV testing strategy that is recommended by the World Health Organization (WHO) for adults and adolescents aged at least 15 years in sub-Saharan Africa for HIV care and prevention. Although studies among adults have been done, there remains a paucity of data of APN service utilization among adolescents in Uganda, yet Adolescents Girls and Young Women (AGYW) have the highest incidence of HIV in Uganda, and generally, adolescents have the lowest HIV viral suppression rates. Failure to disclose to sexual partners poses a risk of propagating infection.

Preferences of people living with HIV for features of tuberculosis preventive treatment regimens in Uganda: a discrete choice experiment.

Introduction: Tuberculosis (TB) preventive treatment (TPT) is recommended for people living with HIV (PLHIV) in high TB burden settings. While 6 months of daily isoniazid remains widely used, shorter regimens are now available. However, little is known about preferences of PLHIV for key features of TPT regimens.

Adverse Events Reported During Weekly Isoniazid-Rifapentine (3HP) Tuberculosis Preventive Treatment Among People With Human Immunodeficiency Virus in Uganda.

Background: Short-course tuberculosis (TB) prevention regimens, including 12 weeks of isoniazid and rifapentine (3HP), are increasingly used in high-TB-burden countries. Despite established safety and tolerability in efficacy trials, 3HP-related adverse events (AEs) could differ in routine settings. Real-world data on AE type, frequency, and timing are crucial for health systems considering 3HP programmatic scale-up.